Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11433100 Compositions and methods for treating ceacam positive cancers

Patent 11433100 was granted and assigned to A2 Biotherapeutics, Inc on September, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

The disclosure provides immune cells comprising a first activator receptor specific to CEA, and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11433100 Compositions and methods for treating ceacam positive cancers

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo